The point is that the company is currently spending aroung 7-8M of cash per quarter. The point is that most of the recent drug partnerships did not mention any upfront milestone payments, and even worse than that, they decided not to disclose any future amount either. The point is that they have an Aspire ATM in place and there's the concrete risk it will be soon used to fund operations, if the company will be unable to raise additional money elsewhere. So while I might share some sort of optimism for the future of the company, I see very little optimism for the future of current shareholders, which is a big difference.
Market Data 
Markets 
AI
